FDA approves Retatrutide this year priced at 2.6% on Polymarket

Approval odds remain low

Polymarket priced FDA approval of Retatrutide this year at 2.6%, with $595K traded, in the supplied market summary published Oct 17, 2026, at 3:09 AM ET. That price reflects a low market-implied likelihood of approval within 2026, rather than an assessment of eventual approval.

The supplied material contains no regulatory announcement or clinical update explaining the price. It also provides no prior price for this contract, so the snapshot does not establish whether traders have recently become more or less optimistic.

Reading the snapshot

According to predictionbubbles.net, PredictionBubbles displays prices from Polymarket and Kalshi and refreshes its data every 15 minutes. The underlying venues trade continuously, meaning a displayed reading can differ from the latest traded price.

PredictionBubbles distinguishes cumulative trading volume from probability movement. The $595K figure describes trading activity in the supplied summary; it does not, by itself, establish the direction of recent sentiment or the strength of the evidence behind the approval odds.

The supplied source page describes the aggregator’s methodology but does not include the Retatrutide contract’s wording or resolution criteria. Those omissions limit how precisely readers can interpret what would qualify as FDA approval for settlement.

What it means for prediction markets

• The deadline is central: The 2.6% reading concerns approval this year, not Retatrutide’s longer-term regulatory prospects.
• Volume is not a trend: $595K traded does not show whether approval odds have risen or fallen.
• Settlement details remain unavailable: The supplied material does not establish the contract’s exact approval standard or resolution process.